Triumvira Immunologics to Present Clinical Data from TACTIC-2 Trial Investigating TAC01-HER2 at ESMO 2023 Congress and AACR-NCI-EORTC International Conference
- Monday, October 2, 2023, 7:01
- Finance
- Add a comment
AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid…
About the Author
adminasapcorp has written 38955 stories on this site.